Combined treatment with orallymecycline and topical adapalene has been shown to induce greater and faster improvement of acne than monotherapy with Iymecycline. We wanted to evaluate the effects of combined therapy with topical adapalene (cream or gel) plus oral Iymecycline used at different dosages (group A: 300mg/day for 2 weeks and then 150mg/day for 14 weeks; group B: 300mg/day for 16 weeks) in 242 patients with inflammatory acne. Both dosage regimens were well tolerated in the majority of patients and significantly improved both the acne lesion count and seborrhoea. There was a trend towards a greater reduction of seborrhoea and nodules in patients of group B. After the initial 16-week phase, patients entered an 8-week follow-up phase, consisting of the use of adapalene monotherapy. The results obtained after this phase confirm the therapeutic value and the favourable tolerability of adapalene as maintenance treatment after successful treatment of inflammatory acne. At the same time, a significantly reduced count of comedones was observed in patients of group B as compared with group A, suggesting that prolonged use of high-dose Iymecycline may have a more pronounced influence on comedogenesis.
Oral tetracyclines are widely used in the treatment of moderate to severe inflammatory acne. Lymecycline is a semisynthetic antibiotic which is converted to tetracycline in the gastrointestinal tract (1) and has been found to be as effective as minocycline for the treatment of inflammatory acne vulgaris (2) (3) . Treatment with lymecycline seems to have potential advantages over other tetracyclines, including a less frequent occurrence of gastrointestinal and dermatological side effects and a better cost/effectiveness rate than minocycline (2) (3) and a lower phototoxicity as compared with doxycycline (4).
Adapalene is a retinoid agent indicated for the topical treatment of acne vulgaris, which is commonly used alone in mild forms or in combination with antibiotics in inflammatory acne. Thanks to additional antiinflammatory properties, adapalene has a favourable tolerability profile compared with other retinoids (5) (6) .
The aim of this study was to compare the efficacy and tolerability of two different 16 week-duration dosing regimens with oral lymecycline, in combination with topical adapalene, in inflammatory acne. After combined treatment, patients underwent a sequential follow-up phase with adapalene alone for 8 weeks. Apart from the role of adapalene as maintenance treatment, differences between the two lymecycline dosing regimens were also assessed in the follow-up phase.
MATERIALS AND METHODS
This open-labelled multicenter study was carried out in patients of both sexes aged 16 years or older with inflammatory acne, who were enrolled since October 2003 and completed study treatment before June 2004. Exclusion criteria consisted of the following conditions: comedonic or mildly inflammatory acne, secondary acne, acne conglobata or fulminans, severe nodulocystic acne, known resistance or contraindications to the use of study medications, hypersensitivity to any ingredients of the study products, use of concomitant treatments apt to interfere with acne lesions, pregnancy and lactation.
After an adequate wash-out period from anti-acne treatments and procedures, patients were consecutively allocated to one of these treatment regimens:
Group A, orallymecycline 300mg once daily (o.d.) for 2 weeks and thereafter 150 mg o.d. for 14 weeks;
Group B, orallymecycline 300mg o.d. for 16 weeks. During this period, patients of both groups received a combined therapy with topical adapalene (gel or cream, 0.1%), o.d., applied at bedtime. Dermatologists chose the type of adapalene formulation in dependence on baseline skin characteristics and/or patient's specific requests. After the 16-week combined treatment, patients underwent a follow-up maintenance phase of 8-week duration, consisting of adapalene alone (gel or cream) which was applied o.d. at bedtime. Patients who experienced a complete cure of acne before the completion of the initial 16-week phase could prematurely discontinue the combined treatment and entered the 8-week follow-up phase.
Patients were visited at the baseline (WO), at week 4 (W4), at the end of the combined therapy (WI6) and after the follow-up phase (W24). Unscheduled visits were performed at any time over the study period for variable reasons, including premature cure or worsening of acne, and adverse events (AEs). At each visit, the investigator assessed the number of acne lesions (comedones, papules, pustules and nodules) and graded the severity of seborrhoea using a 4-score rating scale (0= absent; 1= mild; 2= moderate; 3= notable). Primary efficacy assessment was the variation of acne lesions during treatment in each group, which was analysed under a statistical point of view by the Wilcoxon matched-pairs signed-ranks test (p values <0.05 were considered significant). Differences in clinical parameters between the two groups at each visit were evaluated using the Mann-Whitney test (significance for p values <0.05). Tolerability data were obtained through the description of local and systemic AEs which had to be adequately monitored. At the end of combined treatment and after the follow-up phase, patients and dermatologists gave their independent opinion about the efficacy and tolerability of study treatment.
RESULTS
Study population consisted of 242 patients (135 females and 107 males) with inflammatory acne: 126 in group A and 116 in group B, whose general characteristics are reported in Fig. 1 , which also shows other details of the trial (evaluable patients, premature discontinuations, AEs and topical formulation of adapalene used).
The choice of adapalene formulation was mainly linked to patient's preference or to the presence of sensitive, xerotic or atopic skin, in the case of cream, or seborrhoea, in the case of gel. In the majority of cases, the formulation of adapalene was not changed over the study period, apart from a few patients, most of whom replaced gel with cream because of local AEs or reasons related to cosmetic acceptability.
Baseline clinical characteristics of the two groups were almost similar; in fact, there were nonsignificant differences in the count of acne lesions, with the exception of nodules which were significantly more numerous in group B (p=0.004, Fig. 2) . Moreover, at baseline, patients included in group B presented with a significantly higher degree of seborrhoea as compared with group A (p=0.027, Fig. 3 ). Each regimen of combined therapy caused a statistically significant improvement of all acne lesions (Fig. 2) and seborrhoea ( Fig. 3) at both W4 and W16. At the end of treatment with lymecycline and adapalene, the opinion of patients and dermatologists on the efficacy and tolerability was positive in most cases (Table I) ; interestingly, the group B regimen was considered excellent more frequently by both patients and dermatologists.
Afterwards, in the follow-up phase consisting of the use of adapalene alone, a statistically significant improvement of acne lesions and seborrhoea still persisted and there was a general trend towards a further amelioration as compared with the end of combined therapy (Fig. 2 and Fig. 3 ). During this maintenance phase, acne relapsed in sporadic cases: 3 patients in group A and 5 cases in group B (in three of these the worsening ofacne was ofmoderate intensity). The comparison between the two groups showed a significantly lower number ofcomedones in patients of group B (p=0.034).
Treatment was well tolerated in the majority of cases, with development of relevant AEs in a few cases (Fig. 1) . Systemic AEs, mostly represented by gastrointestinal complaints and possibly related to lymecycline, occurred in 3 patients of group A and 5 of group B. They were mild and transient in all patients but one, who experienced troublesome gastrointestinal symptoms requiring treatment interruption soon after the start of group B regimen. Local AEs were also uncommon and always characterized by a mild to moderate intensity. In isolated cases, AEs linked to adapalene gel were managed by the use of cream formulation. Anyway, adapalene formulation did not affect the overall opinion on efficacy and tolerability of treatment regimens in both phases (data not shown).
DISCUSSION
The results of our study primarily confirm the high efficacy and tolerability of a combined treatment with oral lymecycline and topical adapalene, as previously reported (7) (8) . The additive anti-acne activities of this combination therapy may have relevant influence on patient's satisfaction and compliance (7) .
We evaluated the effects of two different dosing regimens of lymecycline (300 mg o.d. observational period up to 8 weeks of follow-up. Lymecycline 300mg was used in o.d. administration as previous evidences have shown that it is as effective and safe as lymecycline 150mg twice daily, thus favouring patient's compliance and adherence (9) . Each dosing regimen notably improved acne and seborrhoea at both W4 and W16. At baseline, significantly more seborrhoeic and nodular forms were included in group B as compared with group A; nevertheless, the differences between the two groups were not statistically significant during treatment, suggesting a marked therapeutic effect of group B regimen ( Fig. 2 and Fig. 3 ). Interestingly, patients in group B rated the efficacy as excellent more frequently than patients in group A (57% versus 29%); this paralleled the dermatologists' opinion on treatment regimens (Tab. I). Despite the more prolonged use of a double dosage in group B, the frequency and nature of systemic AEs were almost similar for the two groups.
During the 8-week follow-up phase with adapalene monotherapy, the clinical results were maintained or further improved in most cases, highlighting the value of adapalene as maintenance treatment after successful therapy of inflammatory acne (8,I0) . At the same time, the highly favourable tolerability profile of adapalene was also confirmed in our experience (5, 6, 8, 11) . Interestingly, at W24, patients in group B showed a significantly lower number of comedones than patients treated with group A regimen (p=0.034, Fig. 2 ). This finding induce us to hypothesize that prolonged highdose regimen of lymecycline can more efficiently suppress comedo formation in the long term. It is well known that the mechanism of action of tetracyclines in acne is mediated by antimicrobial and antiinflammatory effects but, at the same times, there are hints suggesting a possible suppressive role on comedogenesis, including the modulation of sebum lipids and ostial hyperkeratosis (12-13).
